- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT03584971
Estrogen and Cooperation, Competitiveness, and Risk Preferences (FELICIA)
The Effect of Estrogen Levels on Cooperative and Competitive Decision Making and Risk Preferences
Přehled studie
Postavení
Podmínky
Detailní popis
Behavioural theories assume that, as a result of natural selection, women undergo a brief, unconscious change in some psychological aspects during ovulation. This short-term change, "ovulatory shift", is assumed to aim to increase the probability of successful reproduction in the decisive days of the female cycle. Amongst others, it is assumed that women behave particularly uncooperatively and particularly competitively towards other women during the fertile days. Though, empirical evidence is ambiguous.
The effect on risk preferences is unclear. Theory generally assumes that female risk aversion increases in the fertile days. However, empirical studies find partly positive and partly negative correlations.
Within the scope of this study, estradiol levels which are collected in the clinical treatment of patients in the Clinic for Gynaecological Endocrinology and Reproductive Medicine are to be linked with the behavioural economic measures of cooperation, competitiveness, and risk preferences, which are collected using questionnaires or a computer-based decision task.
The aim of the research project is to quasi-experimentally isolate the effect of estradiol on competitiveness, cooperation and risk preferences of women.
No study known to us has ever been able to realize a comparable quasi-experimental design which is necessary to isolate the causal effect of estradiol on different behavioural measures.
In the experimental group, a sample of approx. 50 women in fertility treatment (In Vitro Fertilization/Intracytoplasmic Sperm Injection (IVF/ICSI), long Gonadotropin releasing Hormone (GnRH) agonist protocol) is surveyed. This allows us to create a quasi-experimental design in which the estradiol level is exogenously manipulated and regularly measured.
A random sample of 30 male students of Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University serves as a control group.
We realize a longitudinal section design with measurement repetitions, which allows inter- and intrapersonal comparisons. A three-stage procedure with two measuring points and a preliminary clarification meeting is planned.
The following measuring instruments are used to record competitiveness, cooperation and risk preference: SOEP Risk Attitude, Social Value Orientation German A, The cooperative and competitive Personality Scale German, Risk aversion, Willingness to compete.
Typ studie
Zápis (Očekávaný)
Kontakty a umístění
Studijní kontakt
- Jméno: Jan Frederik Graff, Dr.
- Telefonní číslo: +492418027066 +49 241 8093341
- E-mail: Frederik.Graff@org.rwth-aachen.de
Studijní záloha kontaktů
- Jméno: Benjamin Rösing, Dr.
- Telefonní číslo: +492418027066 +49 241 80 27066
- E-mail: broesing@ukaachen.de
Studijní místa
-
-
-
Aachen, Německo, 52074
- Nábor
- RWTH Aachen University Hospital
-
Kontakt:
- Jan Frederik Graff, Dr.
- Telefonní číslo: +492418027066 +492418093341
- E-mail: Frederik.Graff@org.rwth-aachen.de
-
Kontakt:
- Benjamin Rösing, Dr.
- Telefonní číslo: +492418027066 +492418027066
- E-mail: broesing@ukaachen.de
-
Vrchní vyšetřovatel:
- Benjamin Rösing
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Metoda odběru vzorků
Studijní populace
Popis
Inclusion Criteria:
Patients
- female
- patient in fertility treatment according to Long GnRH Agonist Protocol
- 18 years and older
- written declaration of consent
- persons who are contractually capable and mentally able and willing to follow the instructions of the study staff
- understanding of the German language (written and spoken)
Control group
- male
- 18 Years and older
- written declaration of consent
- persons who are contractually capable and mentally able and willing to follow the instructions of the study staff
- understanding of the German language (written and spoken)
Exclusion Criteria:
Patients
- Illiterate
- pregnant and breastfeeding women
- persons who are accommodated in an institution on official or court order
- persons in a dependent or employment relationship with the auditor
- simultaneous participation in another clinical trial
Control group
- Illiterate
- persons who are accommodated in an institution on official or court order
- persons in a dependent or employment relationship with the auditor
- simultaneous participation in another clinical trial
Studijní plán
Jak je studie koncipována?
Detaily designu
- Observační modely: Jiný
- Časové perspektivy: Budoucí
Kohorty a intervence
Skupina / kohorta |
---|
female patients
women in fertility treatment according to Long GnRH Agonist Protocol
|
control group
random sample of male students
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Change of E2 [mg/l]
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of blood concentration of estradiol (E2) in mg/l
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of LH [mg/l]
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of blood concentration of the luteinizing hormone (LH) in mg/l
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Prog [mg/l]
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of blood concentration of progesterone (Prog) in mg/l
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Cooperation 1
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of willingness to cooperate measured via the Social Value Orientation German A (Murphy et al. 2011)
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Competitiveness 1
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of willingness to compete measured via the cooperative and competitive Personality Scale German (Lu et al. 2006)
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Risk Preference 1
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Risk preferences measured via the SOEP Risk Attitude (DIW Berlin)
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Cooperation 2
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of willingness to cooperate measured via the cooperative and competitive Personality Scale German (Lu et al. 2006)
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Competitiveness 2
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of willingness to compete measured via the Willingness to compete measure based on Niederle & Vesterlund (2007)
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Risk Preference 2
Časové okno: Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Change of Risk preferences measured via the Risk aversion measure by Holt & Laury (2002)
|
Approx. 10 days after application of GnRH agonist and again approx. 14 days later
|
Spolupracovníci a vyšetřovatelé
Sponzor
Vyšetřovatelé
- Vrchní vyšetřovatel: Benjamin Rösing, Dr., RWTH Aachen
Publikace a užitečné odkazy
Obecné publikace
- Ranehill, E., Zethraeus, N., Blomberg, L., von Schoultz, B., Hirschberg, A. L., Johannesson, M., & Dreber, A. (2017). Hormonal Contraceptives Do Not Impact Economic Preferences: Evidence from a Randomized Trial. Management Science.
- Durante, K. M., Griskevicius, V., Hill, S. E., Perilloux, C., & Li, N. P. (2010). Ovulation, female competition, and product choice: Hormonal influences on consumer behavior. Journal of Consumer Research, 37(6), 921-934.
- Gangestad SW, Thornhill R. Menstrual cycle variation in women's preferences for the scent of symmetrical men. Proc Biol Sci. 1998 May 22;265(1399):927-33. doi: 10.1098/rspb.1998.0380.
- Buser, T. (2012a). Digit ratios, the menstrual cycle and social preferences. Games and Economic Behavior, 76(2), 457-470.
- Buser, T. (2012b). The impact of the menstrual cycle and hormonal contraceptives on competitiveness. Journal of Economic Behavior & Organization, 83(1), 1-10.
- Wozniak, D., Harbaugh, W. T., & Mayr, U. (2014). The menstrual cycle and performance feedback alter gender differences in competitive choices. Journal of Labor Economics, 32(1), 161-198.
- Pearson, M., & Schipper, B. C. (2013). Menstrual cycle and competitive bidding. Games and Economic Behavior, 78, 1-20.
- Drichoutis, A. C., & Nayga, R. M. (2015). Do risk and time preferences have biological roots?. Southern Economic Journal, 82(1), 235-256.
- Lazzaro SC, Rutledge RB, Burghart DR, Glimcher PW. The Impact of Menstrual Cycle Phase on Economic Choice and Rationality. PLoS One. 2016 Jan 29;11(1):e0144080. doi: 10.1371/journal.pone.0144080. eCollection 2016.
- Murphy RO, Ackermann KA. Social value orientation: theoretical and measurement issues in the study of social preferences. Pers Soc Psychol Rev. 2014 Feb;18(1):13-41. doi: 10.1177/1088868313501745. Epub 2013 Sep 23.
- Lu S, Au WT, Jiang F, Xie X, Yam P. Cooperativeness and competitiveness as two distinct constructs: validating the Cooperative and Competitive Personality Scale in a social dilemma context. Int J Psychol. 2013;48(6):1135-47. doi: 10.1080/00207594.2012.743666. Epub 2012 Nov 12.
- Holt, C. A., & Laury, S. K. (2002). Risk aversion and incentive effects. American economic review, 92(5), 1644-1655.
- Niederle, M., & Vesterlund, L. (2007). Do women shy away from competition? Do men compete too much?. The Quarterly Journal of Economics, 1067-1101.
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- 18-053
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
produkt vyrobený a vyvážený z USA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .